Observational studyIndian heart journal
Ultra-low thickness bio-degradable polymer vs durable polymer everolimus eluting stents - A 24 months clinical follow-up study.
Observational study in Indian heart journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A multicenter observational study of 2059 PCI patients compared the ultrathin-strut BDP-EES (Eternia) with the DP-EES (Xience) over 24 months. Patients in the Eternia group were older with more chronic total occlusions. MACE rates were 3.7 % (Xience) vs 3.8 % (Eternia; p = 0.939), with no significant differences in mortality, TVR, or stent thrombosis. No definite or probable stent thrombosis was reported in either group, and possible thrombosis rates were low (0.3 % vs 0.4 %). These findings suggest that biodegradable and durable polymer platforms offer similar long-term performance. The Eternia stents demonstrated equivalent safety and efficacy to Xience stents at 24 months.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.